Status:
UNKNOWN
Ocular Changes in Vitiligo Patients on Therapy
Lead Sponsor:
Benha University
Conditions:
Vitiligo
Chorioretinopathy
Eligibility:
All Genders
18-70 years
Brief Summary
Vitiligo patients on systemic and local therapy may have some ocular adverse effects associated with the disease and its therapy.
Detailed Description
Chorioretinal changes associated with vitiligo therapy could address patients visual acuity and life style. Early detection of these changes can help these patients to evade such adverse effects.
Eligibility Criteria
Inclusion
- vitiligo patients on systemic and local therapy that regularly visit dermatology clinic at banha university.
- normal subjects seeking regular ophthalmic examination at ophthalmology clinic at banha university.
Exclusion
- patients with known chronic retinal diseases that may alter OCT-A parameters as age related macular degeneration and diabetic retinopathies.
- patients that refuse to participate in this study.
Key Trial Info
Start Date :
March 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05335746
Start Date
March 10 2022
End Date
September 30 2022
Last Update
April 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Benha University
Banhā, QA, Egypt, 13511